21778 Federal Register / Vol. 65, No. 79 / Monday, April 24, 2000 / Notices

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and

Digestive and Kidney Diseases; Notice

of Closed Meeting

Pursuant to 10(d) of the Federal

Advisory Committee Act, as amended (5

U.S.C. Appendix 2), notice is hereby

given of the following meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Diabetes and Digestive and Kidney Diseases

Special Emphasis Panel; ZDK1 GRB–B (M1).

Date: May 19, 2000.

Time: 8:00 AM to 5:00 PM.

Agenda: To review and evaluate grant

applications.

Place: Ramada Inn Hotel, 8400 Wisconsin

Avenue, Bethesda, Maryland 20814.

Contact Person: Ned Feder, MD, Scientific

Review Administrator, Review Branch, DEA,

NIDDK, Natcher Building Room 6AS25s,

National Institutes of Health, Bethesda, MD

20892, (301) 594–8890.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.847, Diabetes,

Endocrinology and Metabolic Research,

93.848, Digestive Diseases and Nutrition

Research; 93.849, Kidney Diseases, Urology

and Hematology Research, National Institutes

of Health, HHS)

Dated: April 17, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–10173 Filed 4–21–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Child Health and Human Development

Special Emphasis Panel—A Program of

Investigation into Fragile X Syndrome.

Date: May 11–12, 2000.

Time: 8:00 AM to 5:00 PM.

Agenda: To review and evaluate grant

applications.

Place: The Ritz Carlton Hotel, 181

Peachtree Street, NE, Atlanta, GA 30303.

Contact Person: Norman Chang, PHD,

Scientific Review Administrator, Division of

Scientific Review, National Institute of Child

Health and Human Development, National

Institutes of Health, 6100 Executive Blvd.,

Room 5E03, Bethesda, MD 20892, (301) 496–

1485.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.209, Contraception and

Infertility Loan Repayment Program; 93.864,

Population Research; 93.865, Research for

Mothers and Children; 93.929, Center for

Medical Rehabilitation Research, National

Institutes of Health, HHS)

Dated: April 17, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–10174 Filed 4–21–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; Notice of

Meeting

Pursuant to section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

National Advisory Board on Medical

Rehabilitation Research.

The meeting will be open to the

public, with attendance limited to space

available. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

Name of Committee: National Advisory

Board on Medical Rehabilitation Research.

Date: May 1–2, 2000.

Time: 9:00 a.m. to 12 p.m.

Agenda: The agenda will include reports

by the Director, NICHD and Director,

NCMRR, update on NCMRR Training

activities, discussion of the future of medical

rehabilitation, and other business of the

Board.

Place: Pooks Hill Marriott, 5151 Pooks Hill

Road, Bethesda, MD 20814.

Contact Person: Ralph M. Nitkin, Phd,

Director, BSCD, National Center for Medical

Rehabilitation Research, National Institute of

Child Health and Human Development, NIH,

6100 Building, Room 2A03, Bethesda, MD

20892, (301) 402–4206.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.209, Contraception and

Infertility Loan Repayment Program; 93.864,

Population Research; 93.865, Research for

Mothers and Children; 93.929, Center for

Medical Rehabilitation Research, National

Institutes of Health, HHS)

Dated: April 17, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–10175 Filed 4–21–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: NMR Glomerular Filtration

Test and Kit

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 15 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of a limited field of use

exclusive world-wide license to practice

the invention embodied in U.S. Patent

No. 5,100,646 issued March 31, 1992

(U.S. Patent Application Serial No. 07/

557,038, filed July 25, 1990), entitled

‘‘NMR Glomerular Filtration Test and

Kit’’ to BioPhysics Assay Laboratory,

Inc. of Wellesley, Massachusetts, U.S.A.

These patent rights are assigned to the

United States of America.

DATES: Only written comments and/or

applications for a license which are

received by NIH on or before June 23,

2000 will be considered.

ADDRESSES: Requests for a copy of this

issued patent or applications, inquiries,

comments, and other materials relating

to the contemplated license should be

directed to: Carol A. Salata, Technology

Federal Register / Vol. 65, No. 79 / Monday, April 24, 2000 / Notices 21779

Licensing Specialist, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, MD 20852–3804;

Telephone: (301) 496–7735 ext 232;

Facsimile: (301) 402–0220; E-mail:

salatac@OD.NIH.GOV.

SUPPLEMENTARY INFORMATION: The patent

describes a method of determining the

glomerular filtration rate (GFR) of a

subject that comprises comparing the T1

relaxation rate values of serum and

urine samples obtained from a subject

given an NMR detectable paramagnetic

substance that is filtered by the kidney

in accordance with a specified formula.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. This prospective

exclusive license may be granted unless,

within 60 days from the date of this

published notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

It is anticipated that this license may

be limited to the use of the method for

determining the glomerular filtration

rate of a patient utilizing a paramagnetic

substance that is filtered by the kidney

which is detectable by NMR.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: April 17, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 00–10167 Filed 4–21–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Second Generation

Monoclonal Antibodies, and

Humanized Carcinomas

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health, Department of

Health and Human Services, is

contemplating the grant of an exclusive

license to practice the inventions

embodied in U.S. Patent Applications S/

N 07/073,685, filed on July 15, 1987,

and S/N 07/547,336 (FWC of 07/

07,3,685), filed on July 20, 1990, both

entitled ‘‘Second Generation

Monoclonal Antibodies Having Binding

Specificity to TAG–72 and Human

Carcinomas and Methods for Employing

the Same’’ and now U.S. Patent

5,512,443 which issued on April 30,

1996; and U.S. Provisional Patent

Applications S/N 60/106,534, filed on

October 31, 1998, and S/N 60/106,757,

filed on November 2, 1998, both entitled

‘‘Variants of Humanized AntiCarcinoma MAb CC49’’, and PCT Patent

Application PCT/US99/25552 (based

upon S/N 60/106,534 and 60/106,757)

filed on October 29, 1999, entitled

‘‘Variants of Humanized AntiCarcinoma Monoclonal Antibody CC49’’

to IDEC Pharmaceutical Corporation of

San Diego, California. The patent rights

in these inventions have been assigned

to the United States of America.

The prospective exclusive license

territory will be worldwide and the field

of use may be limited to anti-TAG–72

monoclonal antibodies, including

fragments, components, constituents

and/or humanized variants thereof, and

excluding bispecific monoclonal

antibodies, which are directly

conjugated to a radioactive isotope, for

use as human anti-cancer therapeutics.

DATES: Only written comments and/or

license applications which are received

by the National Institutes of Health on

or before June 23, 2000 will be

considered.

ADDRESSES: Requests for copies of the

patent, inquiries, comments and other

materials relating to the contemplated

exclusive license should be directed to:

Elaine F. Gese, M.B.A., Technology

Licensing Specialist, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, MD 20852–3804.

Telephone: (301) 496–7056, X282;

Facsimile (301) 402–0220; E-mail

eg46t@nih.gov.

SUPPLEMENTARY INFORMATION: U.S.

Patent 5,512,443 claims various ‘‘second

generation’’ monoclonal antibodies,

including CC49, which have binding

specificity to Tumor Associated

Glycoprotein (TAG–72). PCT Patent

Application PCT/US99/25552 claims

humanized variants of CC49, as well as

methods of generating such variants.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within sixty (60) days from the date of

this published notice, the NIH receives

written evidence and argument that

establish that the grant of the license

would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7.

Applications for a license filed in

response to this notice for the noted

field of use will be treated as objections

to the grant of the contemplated

exclusive license. Comments and

objections submitted in response to this

notice will not be made available for

public inspection and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: April 17, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 00–10166 Filed 4–21–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Agency Information Collection

Activities: Proposed Collection;

Comment Request

In compliance with Section

3506(c)(2)(A) of the Paperwork

Reduction Act of 1995 concerning

opportunity for public comment on

proposed collections of information, the

Substance Abuse and Mental Health

Services Administration will publish

periodic summaries of proposed

projects. To request more information

on the proposed projects or to obtain a

copy of the information collection

plans, call the SAMHSA Reports

Clearance Officer on (301) 443–7978.

Comments are invited on: (a) Whether

the proposed collections of information

are necessary for the proper

performance of the functions of the

agency, including whether the

information shall have practical utility;

(b) the accuracy of the agency’s estimate

of the burden of the proposed collection

of information; (c) ways to enhance the

quality, utility, and clarity of the

information to be collected; and (d)

ways to minimize the burden of the

collection of information on

respondents, including through the use

of automated collection techniques or

other forms of information technology.